Content
03/17/2025
Thousand Oaks, CA USA
Latigo Biotherapeutics
completed $150 million Series B Round funding. Investors include
Blue Owl Capital (lead), Deep Track Capital, Access Industries, Qatar Investment Authority, Cormorant Asset Management, Sanofi Ventures, Rock Springs Capital, Kern Capital, Westlake BioPartners, Foresite Capital, 5AM Ventures, Alexandria Venture Investments.
About
Latigo Biotherapeutics is a private clinical-stage biotechnology company developing innovative non-opioid pain medicines with potential best-in-class profiles that directly target the source of pain. Latigo's goal is to provide effective, rapid-acting pain relief without the risk of addiction.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
